MEDICINOVA INC (MNOV) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US58468P2065
MEDICINOVA INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 409,657.00 USD |
| Operating income | -13.28 m USD |
| EBIT | -11.99 m USD |
| Net income | -12.00 m USD |
| Diluted EPS – continuing operations | -0.24 USD |
Full history since 2001, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About MEDICINOVA INC
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
More stocks
- Bangkok Lab & Cosmetic PCL (BLC.BK)
- Marisa Lojas S.A (AMAR3.SA)
- Shih Kuen Plastics Co Ltd (4305.TWO)
- Malindo Feedmill Tbk (MAIN.JK)
- Gossamer Bio, Inc. (GOSS)
- BCP Investment Corp (BCIC)
- China Fineblanking Technology Co Ltd (1586.TWO)
- Arrienda Rental Properties SOCIMI SA (YARP.MC)
- Youngbo Chem (014440.KS)
- FCN Banc Corp (FBVI)
- Highland Copper Company Inc. (HI.V)
- Net Digital AG (VRL.DE)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.